Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Heather Johnson

Cardiovascular Disease Boca Raton, FL Medical Doctor

NPI 1447215785 CMS profile 916632

690 Meadows Rd, Boca Raton, FL 33486

Open in the dashboard

General payments

$30,947

53 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Johnson of Boca Raton, FL is reported in the CMS Open Payments database as having received $30,947 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,931 7
2024 General $23,607 32
2023 General $3,139 10
2020 General $39 2
2019 General $231 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Johnson
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Heather Johnson were reported at $3,931. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Heather Johnson Cardiovascular Disease median Middle half National median
2019 $231 $450 $127–$1,392 $163
2020 $39 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $3,139 $443 $136–$1,283 $160
2024 $23,607 $450 $136–$1,323 $164
2025 $3,931 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Esperion Therapeutics, Inc. $16,669 20 payments
  2. Novartis Pharmaceuticals Corporation $6,523 9 payments
  3. Medtronic, Inc. $5,908 6 payments
  4. Amgen Inc. $1,487 7 payments
  5. Boston Scientific Corporation $169 1 payment
  6. Bayer HealthCare Pharmaceuticals Inc. $86 4 payments
  7. Intuitive Surgical, Inc. $36 1 payment
  8. Teva Pharmaceuticals USA, Inc. $32 2 payments
  9. Exact Sciences Corporation $18 1 payment
  10. Amarin Pharma Inc. $17 1 payment
  11. Other $2 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,355 5 payments
  2. Consulting Fee $13,447 11 payments
  3. Food and Beverage $2,228 34 payments
  4. Travel and Lodging $917 3 payments
Products named General payments · program years 2019–2025
  1. NEXLETOL $16,669 20 payments
  2. NEXLIZET $16,363 16 payments
  3. LEQVIO $2,998 5 payments
  4. Repatha $1,116 4 payments
  5. WATCHMAN FLX $169 1 payment
  6. ENTRESTO $131 1 payment
  7. Mirena $47 2 payments
  8. Kyleena $39 2 payments
  9. Da Vinci Surgical System $36 1 payment
  10. Austedo XR $32 2 payments
  11. Other $37 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,271

Median for Cardiology: 2,533

Drug cost

$144,195

Median for Cardiology: $485,213

Branded share of claims

6.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 44 $34,083
Eliquis Apixaban Brand 32 $30,147
Nexlizet Bempedoic Acid/Ezetimibe Brand 24 $19,166
Xarelto Rivaroxaban Brand 27 $17,429
Jardiance Empagliflozin Brand 13 $13,713
Rosuvastatin Calcium Generic 548 $6,293
Valsartan Generic 218 $6,065
Ezetimibe Generic 265 $5,656
Metoprolol Succinate Generic 255 $3,522
Amlodipine Besylate Generic 258 $1,695

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$65,599

Medicare's payments for the services billed

Medicare patients

358

Average age 74

Services billed

890

299 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Ischemic heart disease 58%
Arthritis 49%
Cancer 30%
Osteoporosis 30%
Diabetes 21%
Chronic kidney disease 18%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NEXLETOL
  • Esperion Therapeutics, Inc. $8,266
$8,266 — —
NEXLIZET
  • Esperion Therapeutics, Inc. $8,181
$8,181 24 —
Repatha
  • Amgen Inc. $927
$927 44 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $66
$66 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record